Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Prostate Cancer
Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study

February 9, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time February 09, 2023
arrow
Proprietary electron accelerator technology achieves “two beams on target” milestone, validating proof of concept for large-scale U.S. Mo-99 production without the use of uranium
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)

January 11, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time January 11, 2023
arrow
Patients for Safer Nuclear Medicine calls NRC ruling a victory, notes work to protect patients is not over
News | Nuclear Imaging
Patient Coalition Applauds Federal Decision Impacting Nuclear Medicine Safety

January 2, 2023 — The federal agency that oversees the administration of nuclear medicine has announced that it will ...

Time January 02, 2023
arrow
Figure 1. The fat pad adjacent to the kneecap (Hoffa's fat pad, infrapatellar fat pad) can change in signal on MRI when the knee is inflamed. (A) Normal knee without signs of inflammation. (B) Arrow pointing on a circumscribed area with higher signal (bright lines) in the area of the fat pad (normally dark), which is indicative of a beginning inflammatory reaction. (C) The whole fat pad has a higher signal (light grey color with white lines), which is a sign of progressive inflammation of the knee joint.
News | RSNA
NSAIDs May Worsen Arthritis Inflammation

November 21, 2022 — Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen ...

Time November 21, 2022
arrow
NorthStar Medical Radioisotopes’ Radiopharmaceutical CDMO in Beloit, Wis. (artist rendering). Upon completion, NorthStar will be first and only U.S. company housing commercial-scale, multi-radioisotope production and radiopharmaceutical development services on the same campus, enabling collaborating companies to realize logistical, regulatory and cost benefits. (Photo: Business Wire)
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Expands Business Platform with New, Patient-focused, Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) Services Unit

November 15, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time November 15, 2022
arrow
The American Society of Nuclear Cardiology has issued an alert about possible supply disruptions
News | Radiopharmaceuticals and Tracers
Alert: Mo-99/Tc-99m Supply Disruptions Possible

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Time November 05, 2022
arrow
18F-rhPSMA-7.3 PET image showing prostate cancer spread beyond the prostate region (Photo courtesy of Blue Earth Diagnostics)
News | PET Imaging
Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

November 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time November 02, 2022
arrow
The oral presentation includes additional results from Blue Earth's Phase 3 SPOTLIGHT study evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy
News | PET Imaging
Blue Earth Diagnostics Highlights Presentations on Axumin (Fluciclovine F 18) and Investigational 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 25, 2022
arrow
The center will be equipped with a Cyclone KIUBE offering the highest production capacity with a PET cyclotron.
News | Radiopharmaceuticals and Tracers
ElsMed, Novatec and IBA Sign Contract to Install Radiopharmaceutical Production Center in Georgia

October 6, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time October 06, 2022
arrow
IBA Rhodotron TT300-HE electron beam accelerator (Photo: Business Wire)
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and IBA Sign Agreement for Two Additional Rhodotron Electron Beam Accelerators for Commercial Production of Radioisotopes

September 22, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time September 22, 2022
arrow
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

August 26, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time August 25, 2022
arrow
NorthStar will provide Clovis with its environmentally preferred, high purity non-carrier-added (n.c.a.) Ac-225
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Announces Supply Agreement with Clovis Oncology for Therapeutic Radioisotope Actinium-225 (Ac-225)

July 20, 2022 — -NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 20, 2022
arrow
SNMMI Elects Cathy Sue Cutler, PhD, FSNMMI, as Vice President-Elect at 2022 Annual Meeting
News | SNMMI
SNMMI elects Cathy Sue Cutler, PhD, FSNMMI, as Vice President-Elect at 2022 Annual Meeting

June 16, 2022 — Cathy Sue Cutler, PhD, FSNMMI, director of the medical isotope research and production program at ...

Time June 16, 2022
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the creation of the Mars Shot Fund, an initiative to raise $100 million to help pay for research into nuclear medicine, molecular imaging, and therapy.
News | SNMMI
SNMMI Launches Mars Shot Fund for Nuclear Medicine Research

June 14, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the creation of the Mars Shot ...

Time June 14, 2022
arrow
SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as President at 2022 Annual Meeting
News | SNMMI
SNMMI elects Munir Ghesani, MD, FACNM, FACR, as President at 2022 Annual Meeting

June 14, 2022 — Munir Ghesani, MD, FACNM, FACR, chief of nuclear medicine and molecular imaging at Mount Sinai Health ...

Time June 14, 2022
arrow
SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences industry that specializes in radiopharmaceuticals, today announced that it will showcase its new Actinium-225 production facility during this year’s annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting being held June 11-14 in Vancouver, British Columbia, Canada.
News | Radiopharmaceuticals and Tracers
SpectronRx to Showcase New Facility for the Global Supply of Actinium-225 at SNMMI 2022

June 13, 2022 — SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences ...

Time June 13, 2022
arrow
Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added (n.c.a.) Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of patients with solid tumors
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and Curie Therapeutics Announce Priority Access Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

June 8, 2022 — NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and ...

Time June 08, 2022
arrow
The global nuclear medicine market size is expected to reach $24.4 billion by 2030, expanding at a CAGR of 13.0% from 2022 to 2030.
Feature | Nuclear Imaging
Global Nuclear Medicine Market Analysis Report

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics ...

Time May 26, 2022
arrow
Oral presentation based on Late-breaking Abstract featured at American Urological Association’s 2022 Annual Meeting (AUA2022)
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
A schematic of the 99Mo/99mTc production system based on an electron linear accelerator and activated carbon-based 99mTc generator
News | Radiopharmaceuticals and Tracers
New Production Method Promises to End Medical Radioisotope Shortages

April 22, 2022 — A commonly used radioisotope, technetium-99m, used in medical diagnoses regularly suffers from ...

Time April 22, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now